Rallybio Corporation

NasdaqCM:RLYB Stock Report

Market Cap: US$83.8m

Rallybio Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Steve Uden

Chief executive officer

US$1.2m

Total compensation

CEO salary percentage51.00%
CEO tenure8.5yrs
CEO ownership1.7%
Management average tenureno data
Board average tenure5.8yrs

Recent management updates

Recent updates

Analysis Article • Jul 10

We're Keeping An Eye On Rallybio's (NASDAQ:RLYB) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Analysis Article • Aug 28

We Think Rallybio (NASDAQ:RLYB) Needs To Drive Business Growth Carefully

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Analysis Article • Jan 04

Is Rallybio (NASDAQ:RLYB) In A Good Position To Deliver On Growth Plans?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Sep 19

Is Rallybio (NASDAQ:RLYB) In A Good Position To Invest In Growth?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Analysis Article • May 15

Here's Why We're Not Too Worried About Rallybio's (NASDAQ:RLYB) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Analysis Article • Jan 30

We Think Rallybio (NASDAQ:RLYB) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Oct 31

Here's Why We're Not Too Worried About Rallybio's (NASDAQ:RLYB) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Analysis Article • Jul 07

Here's Why We're Not Too Worried About Rallybio's (NASDAQ:RLYB) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • Mar 16

Rallybio (NASDAQ:RLYB) Is In A Good Position To Deliver On Growth Plans

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

CEO Compensation Analysis

How has Steve Uden's remuneration changed compared to Rallybio's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

-US$8m

Dec 31 2025US$1mUS$590k

-US$9m

Sep 30 2025n/an/a

-US$14m

Jun 30 2025n/an/a

-US$42m

Mar 31 2025n/an/a

-US$48m

Dec 31 2024US$1mUS$551k

-US$58m

Sep 30 2024n/an/a

-US$67m

Jun 30 2024n/an/a

-US$74m

Mar 31 2024n/an/a

-US$76m

Dec 31 2023US$2mUS$530k

-US$75m

Sep 30 2023n/an/a

-US$71m

Jun 30 2023n/an/a

-US$71m

Mar 31 2023n/an/a

-US$69m

Dec 31 2022US$1mUS$491k

-US$67m

Sep 30 2022n/an/a

-US$63m

Jun 30 2022n/an/a

-US$55m

Mar 31 2022n/an/a

-US$48m

Dec 31 2021US$3mUS$441k

-US$47m

Sep 30 2021n/an/a

-US$45m

Jun 30 2021n/an/a

-US$42m

Mar 31 2021n/an/a

-US$36m

Dec 31 2020US$838kUS$380k

-US$26m

Compensation vs Market: Steve's total compensation ($USD1.16M) is above average for companies of similar size in the US market ($USD659.85K).

Compensation vs Earnings: Steve's compensation has increased whilst the company is unprofitable.

CEO

Steve Uden (68 yo)

8.5yrs
Tenure
US$1,156,968
Compensation

Dr. Stephen Uden, also known as Steve, MD, MBBS, is Chief Executive Officer and Director of Rallybio, LLC since August 01, 2023 and serves as its President. Dr. Uden is a Co-Founder of Rallybio, LLC in 201...

Board Members

NamePositionTenureCompensationOwnership
Martin MacKay
Co-Founder & Chairman8.5yrsUS$297.23k1.73%
$ 1.5m
Stephen Uden
Co-Founder2.9yrsUS$1.16m1.75%
$ 1.5m
Ronald Hunt
Independent Director8.5yrsUS$58.73k0%
$ 0
Robert Hopfner
Independent Director6.3yrsUS$58.73k0%
$ 0
Christine Nash
Independent Director4.3yrsUS$59.83k0%
$ 0
Helen Boudreau
Independent Director5.8yrsUS$62.23k0.056%
$ 47.1k
Lucian Iancovici
Independent Director6.2yrsno datano data
Paula Soteropoulos
Lead Independent Director5.8yrsUS$82.23k0.056%
$ 47.2k
Wendy Chung
Independent Director3.9yrsUS$51.23k0%
$ 0
Hui Liu
Independent Director4.3yrsUS$54.73k0%
$ 0
5.8yrs
Average Tenure
58.5yo
Average Age

Experienced Board: RLYB's board of directors are considered experienced (5.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/06 08:19
End of Day Share Price 2026/07/02 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Rallybio Corporation is covered by 4 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jonathan WollebenCitizens JMP Securities, LLC
Eun Kyung YangJefferies LLC
Ritu BaralTD Cowen